vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and Silvercrest Asset Management Group Inc. (SAMG). Click either name above to swap in a different company.
Silvercrest Asset Management Group Inc. is the larger business by last-quarter revenue ($32.0M vs $23.0M, roughly 1.4× Intellia Therapeutics, Inc.). Silvercrest Asset Management Group Inc. runs the higher net margin — -0.4% vs -416.2%, a 415.8% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -0.0%). Silvercrest Asset Management Group Inc. produced more free cash flow last quarter ($15.0M vs $-69.4M). Over the past eight quarters, Silvercrest Asset Management Group Inc.'s revenue compounded faster (2.7% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
NTLA vs SAMG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $32.0M |
| Net Profit | $-95.8M | $-120.0K |
| Gross Margin | — | — |
| Operating Margin | -428.9% | -2.8% |
| Net Margin | -416.2% | -0.4% |
| Revenue YoY | 78.8% | -0.0% |
| Net Profit YoY | 25.7% | -107.4% |
| EPS (diluted) | $-0.81 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $32.0M | ||
| Q3 25 | $13.8M | $31.3M | ||
| Q2 25 | $14.2M | $30.7M | ||
| Q1 25 | $16.6M | $31.4M | ||
| Q4 24 | $12.9M | $32.0M | ||
| Q3 24 | $9.1M | $30.4M | ||
| Q2 24 | $7.0M | $31.0M | ||
| Q1 24 | $28.9M | $30.3M |
| Q4 25 | $-95.8M | $-120.0K | ||
| Q3 25 | $-101.3M | $618.0K | ||
| Q2 25 | $-101.3M | $1.9M | ||
| Q1 25 | $-114.3M | $2.5M | ||
| Q4 24 | $-128.9M | $1.6M | ||
| Q3 24 | $-135.7M | $2.3M | ||
| Q2 24 | $-147.0M | $2.7M | ||
| Q1 24 | $-107.4M | $3.0M |
| Q4 25 | -428.9% | -2.8% | ||
| Q3 25 | -808.9% | 4.3% | ||
| Q2 25 | -772.2% | 13.2% | ||
| Q1 25 | -726.6% | 15.4% | ||
| Q4 24 | -1059.9% | 6.1% | ||
| Q3 24 | -1589.0% | 14.6% | ||
| Q2 24 | -1998.6% | 17.1% | ||
| Q1 24 | -394.0% | 19.5% |
| Q4 25 | -416.2% | -0.4% | ||
| Q3 25 | -735.2% | 2.0% | ||
| Q2 25 | -710.8% | 6.3% | ||
| Q1 25 | -687.6% | 7.9% | ||
| Q4 24 | -1001.2% | 5.1% | ||
| Q3 24 | -1489.5% | 7.4% | ||
| Q2 24 | -2112.6% | 8.6% | ||
| Q1 24 | -371.3% | 9.9% |
| Q4 25 | $-0.81 | $0.02 | ||
| Q3 25 | $-0.92 | $0.07 | ||
| Q2 25 | $-0.98 | $0.21 | ||
| Q1 25 | $-1.10 | $0.26 | ||
| Q4 24 | $-1.27 | $0.16 | ||
| Q3 24 | $-1.34 | $0.24 | ||
| Q2 24 | $-1.52 | $0.28 | ||
| Q1 24 | $-1.12 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | $44.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $671.4M | $50.3M |
| Total Assets | $842.1M | $166.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | $44.1M | ||
| Q3 25 | $511.0M | $36.1M | ||
| Q2 25 | $459.7M | $30.0M | ||
| Q1 25 | $503.7M | $36.3M | ||
| Q4 24 | $601.5M | $68.6M | ||
| Q3 24 | $658.1M | $58.1M | ||
| Q2 24 | $691.1M | $49.9M | ||
| Q1 24 | $791.3M | $39.7M |
| Q4 25 | $671.4M | $50.3M | ||
| Q3 25 | $748.4M | $58.9M | ||
| Q2 25 | $715.3M | $64.6M | ||
| Q1 25 | $779.9M | $80.0M | ||
| Q4 24 | $872.0M | $80.7M | ||
| Q3 24 | $962.6M | $84.6M | ||
| Q2 24 | $971.1M | $85.3M | ||
| Q1 24 | $1.0B | $83.9M |
| Q4 25 | $842.1M | $166.6M | ||
| Q3 25 | $925.3M | $157.6M | ||
| Q2 25 | $898.9M | $152.7M | ||
| Q1 25 | $986.2M | $159.9M | ||
| Q4 24 | $1.2B | $194.4M | ||
| Q3 24 | $1.2B | $184.2M | ||
| Q2 24 | $1.2B | $177.6M | ||
| Q1 24 | $1.3B | $170.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $18.6M |
| Free Cash FlowOCF − Capex | $-69.4M | $15.0M |
| FCF MarginFCF / Revenue | -301.6% | 46.9% |
| Capex IntensityCapex / Revenue | 0.5% | 11.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | $17.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | $18.6M | ||
| Q3 25 | $-76.9M | $14.6M | ||
| Q2 25 | $-99.6M | $13.8M | ||
| Q1 25 | $-148.9M | $-24.7M | ||
| Q4 24 | $-85.2M | $21.6M | ||
| Q3 24 | $-84.8M | $13.3M | ||
| Q2 24 | $-58.2M | $16.0M | ||
| Q1 24 | $-120.7M | $-24.1M |
| Q4 25 | $-69.4M | $15.0M | ||
| Q3 25 | $-76.9M | $13.8M | ||
| Q2 25 | $-99.9M | $13.4M | ||
| Q1 25 | $-149.7M | $-25.1M | ||
| Q4 24 | $-86.2M | $19.9M | ||
| Q3 24 | $-86.1M | $12.9M | ||
| Q2 24 | $-59.2M | $15.6M | ||
| Q1 24 | $-123.2M | $-24.7M |
| Q4 25 | -301.6% | 46.9% | ||
| Q3 25 | -558.2% | 44.1% | ||
| Q2 25 | -701.0% | 43.6% | ||
| Q1 25 | -900.1% | -80.0% | ||
| Q4 24 | -669.4% | 62.2% | ||
| Q3 24 | -945.2% | 42.4% | ||
| Q2 24 | -850.9% | 50.4% | ||
| Q1 24 | -425.7% | -81.6% |
| Q4 25 | 0.5% | 11.4% | ||
| Q3 25 | 0.2% | 2.6% | ||
| Q2 25 | 1.7% | 1.5% | ||
| Q1 25 | 4.4% | 1.3% | ||
| Q4 24 | 7.6% | 5.3% | ||
| Q3 24 | 14.0% | 1.2% | ||
| Q2 24 | 14.5% | 1.1% | ||
| Q1 24 | 8.7% | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 23.62× | ||
| Q2 25 | — | 7.22× | ||
| Q1 25 | — | -10.01× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | — | 5.90× | ||
| Q2 24 | — | 6.00× | ||
| Q1 24 | — | -8.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
SAMG
| Investment Advisory Management And Administrative Service | $30.7M | 96% |
| Tax And Family Office Services | $1.2M | 4% |
